Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

…, KD Mansfield, D Patsch, RK Amaravadi, LM Schuchter… - Nature, 2015 - nature.com
Immune checkpoint inhibitors 1 result in impressive clinical responses 2 , 3 , 4 , 5 , but
optimal results will require combination with each other 6 and other therapies. This raises …

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response

…, GC Karakousis, TC Mitchell, LM Schuchter, M Herlyn… - Nature, 2018 - nature.com
Tumour cells evade immune surveillance by upregulating the surface expression of programmed
death-ligand 1 (PD-L1), which interacts with programmed death-1 (PD-1) receptor on T …

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

…, RK Amaravadi, GC Karakousis, LM Schuchter… - Nature, 2017 - nature.com
Despite the success of monotherapies based on blockade of programmed cell death 1 (PD-1)
in human melanoma, most patients do not experience durable clinical benefit. Pre-existing …

TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion

…, X Xu, GC Karakousis, TC Mitchell, LM Schuchter… - Nature, 2019 - nature.com
Exhausted CD8 + T (T ex ) cells in chronic infections and cancer have limited effector
function, high co-expression of inhibitory receptors and extensive transcriptional changes …

[PDF][PDF] Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade

…, TC Gangadhar, RK Amaravadi, LM Schuchter… - Cell, 2016 - cell.com
Therapeutic blocking of the PD1 pathway results in significant tumor responses, but
resistance is common. We demonstrate that prolonged interferon signaling orchestrates PDL1-…

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

…, CB Begg, SS Agarwala, LM Schuchter… - Journal of Clinical …, 1999 - ascopubs.org
PURPOSE: Several single-institution phase II trials have reported that the Dartmouth regimen
(dacarbazine, cisplatin, carmustine, and tamoxifen) can induce major tumor responses in …

[PDF][PDF] Developmental relationships of four exhausted CD8+ T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms

…, X Xu, GC Karakousis, TC Mitchell, LM Schuchter… - Immunity, 2020 - cell.com
CD8 + T cell exhaustion is a major barrier to current anti-cancer immunotherapies. Despite
this, the developmental biology of exhausted CD8 + T cells (Tex) remains poorly defined, …

[PDF][PDF] American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants

…, A Trotti III, D Von Hoff, LM Schuchter - Journal of clinical …, 2009 - kaim.or.kr
… Wasserman TH, Brizel DM, Henke M, et al: Influence of intravenous amifostine on
xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year …

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma

…, GP Linette, RK Amaravadi, LM Schuchter… - Nature medicine, 2019 - nature.com
Immunologic responses to anti-PD-1 therapy in melanoma patients occur rapidly with
pharmacodynamic T cell responses detectable in blood by 3 weeks. It is unclear, however, …

Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline

…, KM McMasters, RD Noyes, LM Schuchter… - Annals of surgical …, 2012 - Springer
Purpose The American Society of Clinical Oncology (ASCO) and Society of Surgical Oncology
(SSO) sought to provide an evidence-based guideline on the use of lymphatic mapping …